Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) EPS (Basic) (2016 - 2025)

United Therapeutics (UTHR) has disclosed EPS (Basic) for 17 consecutive years, with $8.37 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 24.74% to $8.37 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.14 through Dec 2025, up 14.08% year-over-year, with the annual reading at $30.13 for FY2025, 13.96% up from the prior year.
  • EPS (Basic) hit $8.37 in Q4 2025 for United Therapeutics, up from $7.73 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $8.37 in Q4 2025 to a low of $0.63 in Q1 2021.
  • Historically, EPS (Basic) has averaged $5.21 across 5 years, with a median of $5.42 in 2022.
  • Biggest five-year swings in EPS (Basic): crashed 79.94% in 2021 and later skyrocketed 742.86% in 2022.
  • Year by year, EPS (Basic) stood at $2.48 in 2021, then grew by 14.52% to $2.84 in 2022, then surged by 61.97% to $4.6 in 2023, then surged by 45.87% to $6.71 in 2024, then grew by 24.74% to $8.37 in 2025.
  • Business Quant data shows EPS (Basic) for UTHR at $8.37 in Q4 2025, $7.73 in Q3 2025, and $6.86 in Q2 2025.